

Treatment Modality

Drug/Target

Target Validation


Preclinical Asset

Trail Phase

FDA Approval



1 2 3

 **Small Molecule**

Ruxolitinib  
Vitiligo



Incyte

 **Antibody**

IL-15  
Vitiligo



Villarix

Acquired in 2022

 **Bispecific Antibody**

DSG3-IFNg  
Vitiligo



\*available\*

 **siRNA**

AIM2  
Melanoma



\*available\*

IFNgR  
Vitiligo



Aldena

**Helminth Products**

IFNgR  
Vitiligo

\*available\*

Many



Clickable to publication